Pulmonary hypertension is a rare and serious disease in which the pressure in the pulmonary (lung) circulation is higher than normal. Without treatment, pulmonary hypertension can cause permanent lung damage, resulting in life-threatening heart failure. Patients with pulmonary hypertension need specialist care, like that found at NewYork-Presbyterian. Combining the expertise of pulmonary hypertension experts with the latest technologies and all of the resources available at one of the world's most renowned academic medical centers, we can provide you with sophisticated, personalized care designed to meet your needs.
A Team of Specialists
Our pulmonary hypertension team, lead by Dr. Erika Berman Rosenzweig, Director of the Pulmonary Hypertension Center at NewYork-Presbyterian/Columbia University Irving Medical Center and the CTEPH Program at Columbia University Irving Medical Center, includes cardiologists, pulmonologists, surgeons, interventional cardiologists, rheumatologists and other consultants with expertise in pulmonary hypertension related diseases and complications, as well as critical care anesthesiologists to assist with non-cardiac surgery. You can receive coordinated health care for this complex condition in one medical center.
NewYork-Presbyterian’s Pulmonary Hypertension Centers are accredited by the Pulmonary Hypertension Association as a designated Tier 1 Pulmonary Hypertension Comprehensive Care Center and are the only centers in New York to receive this accreditation and amongst the first pulmonary hypertension programs in the nation to become accredited.
NewYork-Presbyterian/Columbia University Irving Medical Center has the only multidisciplinary program for chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary thromboendarterectomy (PTE) in our region. Our multidisciplinary team of medical and surgical specialists tailor your therapy to your needs, medical, surgical and interventional treatments, as indicated.
- Medical. As our understanding of pulmonary hypertension increases, new treatment options are being developed at a rapid pace. Today there are oral, inhaled, intravenous, and subcutaneous medications available.
- Surgical. We are one of the few U.S. centers and one of the largest in the country performing pulmonary thromboendarterectomy (PTE) to clear the pulmonary arteries of clots. We have performed over 220 pulmonary thromboendarterectomy surgeries, with excellent outcomes. We also offer lung transplantation and supportive therapy with extracorporeal membrane oxygenation (ECMO). The ECMO program at Columbia University is one of five adult ECMO centers in the world designated a Platinum Level Center of Excellence by the Extracorporeal Life Support Organization (ELSO) for Excellence in Extracorporeal Life Support.
- Interventional. We are one of the few U.S. centers performing balloon pulmonary angioplasty (BPA) for CTEPH. BPA is a lesser invasive alternative for patients who either too high risk for pulmonary artery thromboendarterectomy or have had a recurrence of symptoms after surgery. We have performed over 40 procedures at NewYork-Presbyterian since the start of the program in 2016.
NewYork–Presbyterian offers the entire spectrum of services for patients with thromboembolic diseases and is now part of the Pulmonary Embolism Response Team (PERT) consortium. We have acute pulmonary embolism protocols including clot lysis, acute surgical embolectomy where appropriate with ECMO support as needed, and a team to provide close follow-up.
The pulmonary hypertension team also has extensive experience in co-management of pulmonary hypertension associated with congenital, rheumatologic, inflammatory, oncological diseases and other primary respiratory disorders. The pulmonary hypertension team also assists in the management of complex pregnancies with patients who have pulmonary hypertension.
Education and Support
Our doctors and nurses educate and help you and your caregivers about your treatment and life with pulmonary hypertension. We also believe that a collaborative relationship with your referring physician is critical to ensure you receive the best care. Our team also educates other healthcare providers at the local, national, and international levels about advances occurring in pulmonary hypertension care. Our advocacy for support, education, and research directly affects our patients.
Experts in the Genetics of Pulmonary Hypertension
Our researchers have long been leaders in the field of genetic discovery in pulmonary arterial hypertension and reported the very first mutation associated with inherited forms of pulmonary hypertension. We collaborate closely with our medical genetics experts to provide genetic counseling and testing for patients and families with inherited forms of pulmonary hypertension.
Advancing the Field through Research
We remain at the forefront of clinical research related to pulmonary hypertension. In fact, our center has participated in most of the clinical trials to date evaluating new medical treatments, including the first drug approved for pulmonary hypertension—intravenous epoprostenol—in 1995. We're now pursuing studies of newer oral and inhaled therapies, and participating in several scientific studies to explore novel mechanisms underlying pulmonary arterial hypertension. You may have the opportunity to participate in a clinical trial assessing a promising new treatment.